Pier Francesco Bassi

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

Yair Lotan, Shahrokh F. Shariat, Bernd J. Schmitz‐Dräger et al. · Urologic Oncology Seminars and Original Investigations · 2010 · 106 citations

Medicine, Oncology, Urology +16

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese et al. · BMC Cancer · 2018 · 82 citations · Full text

Medicine, Oncology, Urology +13

Epigenetic silencing of <i>SOCS3</i> identifies a subset of prostate cancer with an aggressive behavior

Francesco Pierconti, Maurizio Martini, Francesco Pinto et al. · The Prostate · 2010 · 78 citations

Life Sciences, Molecular Biology, Oncology +17

MALAT1 and HOTAIR Long Non-Coding RNAs Play Opposite Role in Estrogen-Mediated Transcriptional Regulation in Prostate Cancer Cells

Aurora Aiello, Lorenza Bacci, Agnese Re et al. · Scientific Reports · 2016 · 73 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17

Successful Repair of Iatrogenic Rectourinary Fistulas Using the Posterior Sagittal Transrectal Approach (York‐Mason): 15‐Year Experience

Fabrizio Moro, Mariangela Mancini, Francesco Pinto et al. · World Journal of Surgery · 2005 · 63 citations · Full text

Medicine, Surgery, Reconstructive Surgery +9